More recently, the mineralocorticoid receptor antagonist finerenone has similarly been found to improve cardiovascular [1] and kidney [2] outcomes in people with Type 2 diabetes and chronic kidney disease (CKD), as have glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) [3, 4]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.